J. Safra Sarasin Holding AG Sells 19,163 Shares of Elevance Health, Inc. $ELV

J. Safra Sarasin Holding AG trimmed its position in Elevance Health, Inc. (NYSE:ELV) by 57.1% during the third quarter, Holdings Channel reports. The firm owned 14,401 shares of the company’s stock after selling 19,163 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Elevance Health were worth $4,653,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Vermillion & White Wealth Management Group LLC lifted its holdings in Elevance Health by 94.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the last quarter. BOK Financial Private Wealth Inc. bought a new position in shares of Elevance Health in the second quarter valued at about $32,000. Motco lifted its stake in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares during the last quarter. True Wealth Design LLC grew its stake in Elevance Health by 431.8% in the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company’s stock valued at $38,000 after buying an additional 95 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc raised its holdings in Elevance Health by 400.0% in the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after acquiring an additional 80 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price objective on Elevance Health from $403.00 to $424.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. The Goldman Sachs Group started coverage on Elevance Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price objective on the stock. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Barclays raised their price target on shares of Elevance Health from $385.00 to $404.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Finally, Zacks Research raised shares of Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Twelve investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $399.63.

Elevance Health Stock Down 14.4%

ELV stock opened at $322.55 on Wednesday. The company has a market cap of $71.68 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 1.94 and a beta of 0.51. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75. The business has a 50-day simple moving average of $350.06 and a 200 day simple moving average of $328.78.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating the consensus estimate of $3.07 by $0.26. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.